

.....
(Original Signature of Member)

115TH CONGRESS
2D SESSION

H. R.

To amend title XVIII of the Social Security Act to provide for the review and adjustment of payments under the Medicare outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mrs. WALORSKI (for herself and Ms. JUDY CHU of California) introduced the following bill; which was referred to the Committee on

A BILL

To amend title XVIII of the Social Security Act to provide for the review and adjustment of payments under the Medicare outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Dr. Todd Graham Pain
5 Management, Treatment, and Recovery Act of 2018”.

1 **SEC. 2. REVIEW AND ADJUSTMENT OF PAYMENTS UNDER**
2 **THE MEDICARE OUTPATIENT PROSPECTIVE**
3 **PAYMENT SYSTEM TO AVOID FINANCIAL IN-**
4 **CENTIVES TO USE OPIOIDS INSTEAD OF NON-**
5 **OPIOID ALTERNATIVE TREATMENTS.**

6 (a) OUTPATIENT PROSPECTIVE PAYMENT SYS-
7 TEM.—Section 1833(t) of the Social Security Act (42
8 U.S.C. 1395l(t)) is amended by adding at the end the fol-
9 lowing new paragraph:

10 “(22) REVIEW AND REVISIONS OF PAYMENTS
11 FOR NON-OPIOID ALTERNATIVE TREATMENTS.—

12 “(A) IN GENERAL.—With respect to pay-
13 ments made under this subsection for covered
14 OPD services (or groups of services), including
15 covered OPD services assigned to a comprehen-
16 sive ambulatory payment classification, the Sec-
17 retary—

18 “(i) shall, as soon as practicable, con-
19 duct a review (part of which may include
20 a request for information) of payments for
21 opioids and evidence-based non-opioid al-
22 ternatives for pain management (including
23 drugs and devices, nerve blocks, surgical
24 injections, and neuromodulation) with a
25 goal of ensuring that there are not finan-

1 cial incentives to use opioids instead of
2 non-opioid alternatives;

3 “(ii) may, as the Secretary determines
4 appropriate, conduct subsequent reviews of
5 such payments; and

6 “(iii) shall consider the extent to
7 which revisions under this subsection to
8 such payments (such as the creation of ad-
9 ditional groups of covered OPD services to
10 classify separately those procedures that
11 utilize opioids and non-opioid alternatives
12 for pain management) would reduce pay-
13 ment incentives to use opioids instead of
14 non-opioid alternatives for pain manage-
15 ment.

16 “(B) PRIORITY.—In conducting the review
17 under clause (i) of subparagraph (A) and con-
18 sidering revisions under clause (iii) of such sub-
19 paragraph, the Secretary shall focus on covered
20 OPD services (or groups of services) assigned
21 to a comprehensive ambulatory payment classi-
22 fication, ambulatory payment classifications
23 that primarily include surgical services, and
24 other services determined by the Secretary

1 which generally involve treatment for pain man-
2 agement.

3 “(C) REVISIONS.—If the Secretary identi-
4 fies revisions to payments pursuant to subpara-
5 graph (A)(iii), the Secretary shall, as deter-
6 mined appropriate, begin making such revisions
7 for services furnished on or after January 1,
8 2020. Revisions under the previous sentence
9 shall be treated as adjustments for purposes of
10 application of paragraph (9)(B).

11 “(D) RULES OF CONSTRUCTION.—Nothing
12 in this paragraph shall be construed to preclude
13 the Secretary—

14 “(i) from conducting a demonstration
15 before making the revisions described in
16 subparagraph (C); or

17 “(ii) prior to implementation of this
18 paragraph, from changing payments under
19 this subsection for covered OPD services
20 (or groups of services) which include
21 opioids or non-opioid alternatives for pain
22 management.”.

23 (b) AMBULATORY SURGICAL CENTERS.—Section
24 1833(i) of the Social Security Act (42 U.S.C. 1395l(i))

1 is amended by adding at the end the following new para-
2 graph:

3 “(8) The Secretary shall conduct a similar type of
4 review as required under paragraph (22) of section
5 1833(t), including the second sentence of subparagraph
6 (C) of such paragraph, to payment for services under this
7 subsection, and make such revisions under this paragraph,
8 in an appropriate manner (as determined by the Sec-
9 retary).”.

10 **SEC. 3. EXPANDING ACCESS UNDER THE MEDICARE PRO-**
11 **GRAM TO ADDICTION TREATMENT IN FEDER-**
12 **ALLY QUALIFIED HEALTH CENTERS AND**
13 **RURAL HEALTH CLINICS.**

14 (a) **FEDERALLY QUALIFIED HEALTH CENTERS.—**
15 Section 1834(o) of the Social Security Act (42 U.S.C.
16 1395m(o)) is amended by adding at the end the following
17 new paragraph:

18 “(3) **ADDITIONAL PAYMENTS FOR CERTAIN**
19 **FQHCS WITH PHYSICIANS OR OTHER PRACTITIONERS**
20 **RECEIVING DATA 2000 WAIVERS.—**

21 “(A) **IN GENERAL.—**In the case of a Fed-
22 erally qualified health center with respect to
23 which, beginning on or after January 1, 2019,
24 Federally-qualified health center services (as de-
25 fined in section 1861(aa)(3)) are furnished for

1 the treatment of opioid use disorder by a physi-
2 cian or practitioner who meets the requirements
3 described in subparagraph (C) the Secretary
4 shall, subject to availability of funds under sub-
5 paragraph (D), make a payment (at such time
6 and in such manner as specified by the Sec-
7 retary) to such Federally qualified health center
8 after receiving and approving an application
9 submitted by such Federally qualified health
10 center under subparagraph (B). Such a pay-
11 ment shall be in an amount determined by the
12 Secretary, based on an estimate of the average
13 costs of training for purposes of receiving a
14 waiver described in subparagraph (C)(ii). Such
15 a payment may be made only one time with re-
16 spect to each such physician or practitioner.

17 “(B) APPLICATION.—In order to receive a
18 payment described in subparagraph (A), a Fed-
19 erally-qualified health center shall submit to the
20 Secretary an application for such a payment at
21 such time, in such manner, and containing such
22 information as specified by the Secretary. A
23 Federally-qualified health center may apply for
24 such a payment for each physician or practi-
25 tioner described in subparagraph (A) furnishing

1 services described in such subparagraph at such
2 center.

3 “(C) REQUIREMENTS.—For purposes of
4 subparagraph (A), the requirements described
5 in this subparagraph, with respect to a physi-
6 cian or practitioner, are the following:

7 “(i) The physician or practitioner is
8 employed by or working under contract
9 with a Federally qualified health center de-
10 scribed in subparagraph (A) that submits
11 an application under subparagraph (B).

12 “(ii) The physician or practitioner
13 first receives a waiver under section 303(g)
14 of the Controlled Substances Act on or
15 after January 1, 2019.

16 “(D) FUNDING.—For purposes of making
17 payments under this paragraph, there are ap-
18 propriated, out of amounts in the Treasury not
19 otherwise appropriated, \$6,000,000, which shall
20 remain available until expended.”.

21 (b) RURAL HEALTH CLINIC.—Section 1833 of the
22 Social Security Act (42 U.S.C. 1395l) is amended—

23 (1) by redesignating the subsection (z) relating
24 to medical review of spinal subluxation services as
25 subsection (aa); and

1 (2) by adding at the end the following new sub-
2 section:

3 “(bb) ADDITIONAL PAYMENTS FOR CERTAIN RURAL
4 HEALTH CLINICS WITH PHYSICIANS OR PRACTITIONERS
5 RECEIVING DATA 2000 WAIVERS.—

6 “(1) IN GENERAL.—In the case of a rural
7 health clinic with respect to which, beginning on or
8 after January 1, 2019, rural health clinic services
9 (as defined in section 1861(aa)(1)) are furnished for
10 the treatment of opioid use disorder by a physician
11 or practitioner who meets the requirements de-
12 scribed in paragraph (3), the Secretary shall, subject
13 to availability of funds under paragraph (4), make
14 a payment (at such time and in such manner as
15 specified by the Secretary) to such rural health clinic
16 after receiving and approving an application de-
17 scribed in paragraph (2). Such payment shall be in
18 an amount determined by the Secretary, based on an
19 estimate of the average costs of training for pur-
20 poses of receiving a waiver described in paragraph
21 (3)(B). Such payment may be made only one time
22 with respect to each such physician or practitioner.

23 “(2) APPLICATION.—In order to receive a pay-
24 ment described in paragraph (1), a rural health clin-
25 ic shall submit to the Secretary an application for

1 such a payment at such time, in such manner, and
2 containing such information as specified by the Sec-
3 retary. A rural health clinic may apply for such a
4 payment for each physician or practitioner described
5 in paragraph (1) furnishing services described in
6 such paragraph at such clinic.

7 “(3) REQUIREMENTS.—For purposes of para-
8 graph (1), the requirements described in this para-
9 graph, with respect to a physician or practitioner,
10 are the following:

11 “(A) The physician or practitioner is em-
12 ployed by or working under contract with a
13 rural health clinic described in paragraph (1)
14 that submits an application under paragraph
15 (2).

16 “(B) The physician or practitioner first re-
17 ceives a waiver under section 303(g) of the
18 Controlled Substances Act on or after January
19 1, 2019.

20 “(4) FUNDING.—For purposes of making pay-
21 ments under this subsection, there are appropriated,
22 out of amounts in the Treasury not otherwise appro-
23 priated, \$2,000,000, which shall remain available
24 until expended.”.

1 **SEC. 4. STUDYING THE AVAILABILITY OF SUPPLEMENTAL**
2 **BENEFITS DESIGNED TO TREAT OR PREVENT**
3 **SUBSTANCE USE DISORDERS UNDER MEDI-**
4 **CARE ADVANTAGE PLANS.**

5 (a) IN GENERAL.—Not later than 2 years after the
6 date of the enactment of this Act, the Secretary of Health
7 and Human Services (in this section referred to as the
8 “Secretary”) shall submit to Congress a report on the
9 availability of supplemental health care benefits (as de-
10 scribed in section 1852(a)(3)(A) of the Social Security Act
11 (42 U.S.C. 1395w–22(a)(3)(A))) designed to treat or pre-
12 vent substance use disorders under Medicare Advantage
13 plans offered under part C of title XVIII of such Act. Such
14 report shall include the analysis described in subsection
15 (c) and any differences in the availability of such benefits
16 under specialized MA plans for special needs individuals
17 (as defined in section 1859(b)(6) of such Act (42 U.S.C.
18 1395w–28(b)(6))) offered to individuals entitled to med-
19 ical assistance under title XIX of such Act and other such
20 Medicare Advantage plans.

21 (b) CONSULTATION.—The Secretary shall develop the
22 report described in subsection (a) in consultation with rel-
23 evant stakeholders, including—

24 (1) individuals entitled to benefits under part A
25 or enrolled under part B of title XVIII of the Social
26 Security Act;

1 (2) entities who advocate on behalf of such indi-
2 viduals;

3 (3) Medicare Advantage organizations;

4 (4) pharmacy benefit managers; and

5 (5) providers of services and suppliers (as such
6 terms are defined in section 1861 of such Act (42
7 U.S.C. 1395x)).

8 (c) CONTENTS.—The report described in subsection
9 (a) shall include an analysis on the following:

10 (1) The extent to which plans described in such
11 subsection offer supplemental health care benefits
12 relating to coverage of—

13 (A) medication-assisted treatments for
14 opioid use, substance use disorder counseling,
15 peer recovery support services, or other forms
16 of substance use disorder treatments (whether
17 furnished in an inpatient or outpatient setting);
18 and

19 (B) non-opioid alternatives for the treat-
20 ment of pain.

21 (2) Challenges associated with such plans offer-
22 ing supplemental health care benefits relating to cov-
23 erage of items and services described in subpara-
24 graph (A) or (B) of paragraph (1).

1 (3) The impact, if any, of increasing the appli-
2 cable rebate percentage determined under section
3 1854(b)(1)(C) of the Social Security Act (42 U.S.C.
4 1395w-24(b)(1)(C)) for plans offering such benefits
5 relating to such coverage would have on the avail-
6 ability of such benefits relating to such coverage of-
7 fered under Medicare Advantage plans.

8 (4) Potential ways to improve upon such cov-
9 erage or to incentivize such plans to offer additional
10 supplemental health care benefits relating to such
11 coverage.

12 **SEC. 5. CLINICAL PSYCHOLOGIST SERVICES MODELS**
13 **UNDER THE CENTER FOR MEDICARE AND**
14 **MEDICAID INNOVATION; GAO STUDY AND RE-**
15 **PORT.**

16 (a) CMI MODELS.—Section 1115A(b)(2)(B) of the
17 Social Security Act (42 U.S.C. 1315a(b)(2)(B) is amend-
18 ed by adding at the end the following new clauses:

19 “(xxv) Supporting ways to familiarize
20 individuals with the availability of coverage
21 under part B of title XVIII for qualified
22 psychologist services (as defined in section
23 1861(ii)).

24 “(xxvi) Exploring ways to avoid un-
25 necessary hospitalizations or emergency de-

1 partment visits for mental and behavioral
2 health services (such as for treating de-
3 pression) through use of a 24-hour, 7-day
4 a week help line that may inform individ-
5 uals about the availability of treatment op-
6 tions, including the availability of qualified
7 psychologist services (as defined in section
8 1861(ii)).”.

9 (b) GAO STUDY AND REPORT.—Not later than 18
10 months after the date of the enactment of this Act, the
11 Comptroller General of the United States shall conduct
12 a study, and submit to Congress a report, on mental and
13 behavioral health services under the Medicare program
14 under title XVIII of the Social Security Act, including an
15 examination of the following:

16 (1) Information about services furnished by
17 psychiatrists, clinical psychologists, and other profes-
18 sionals.

19 (2) Information about ways that Medicare bene-
20 ficiaries familiarize themselves about the availability
21 of Medicare payment for qualified psychologist serv-
22 ices (as defined in section 1861(ii) of the Social Se-
23 curity Act (42 U.S.C. 1395x(ii)) and ways that the
24 provision of such information could be improved.

1 **SEC. 6. PAIN MANAGEMENT STUDY.**

2 (a) IN GENERAL.—Not later than 1 year after the
3 date of enactment of this Act, the Secretary of Health and
4 Human Services (referred to in this section as the “Sec-
5 retary”) shall conduct a study analyzing best practices as
6 well as payment and coverage for pain management serv-
7 ices under title XVIII of the Social Security Act and sub-
8 mit to the Committee on Ways and Means and the Com-
9 mittee on Energy and Commerce of the House of Rep-
10 resentatives and the Committee on Finance of the Senate
11 a report containing options for revising payment to pro-
12 viders and suppliers of services and coverage related to
13 the use of multi-disciplinary, evidence-based, non-opioid
14 treatments for acute and chronic pain management for in-
15 dividuals entitled to benefits under part A or enrolled
16 under part B of title XVIII of the Social Security Act.
17 The Secretary shall make such report available on the
18 public website of the Centers for Medicare & Medicaid
19 Services.

20 (b) CONSULTATION.—In developing the report de-
21 scribed in subsection (a), the Secretary shall consult
22 with—

23 (1) relevant agencies within the Department of
24 Health and Human Services;

25 (2) licensed and practicing osteopathic and
26 allopathic physicians, behavioral health practitioners,

1 physician assistants, nurse practitioners, dentists,
2 pharmacists, and other providers of health services;

3 (3) providers and suppliers of services (as such
4 terms are defined in section 1861 of the Social Secu-
5 rity Act (42 U.S.C. 1395x));

6 (4) substance abuse and mental health profes-
7 sional organizations;

8 (5) pain management professional organizations
9 and advocacy entities, including individuals who per-
10 sonally suffer chronic pain;

11 (6) medical professional organizations and med-
12 ical specialty organizations;

13 (7) licensed health care providers who furnish
14 alternative pain management services;

15 (8) organizations with expertise in the develop-
16 ment of innovative medical technologies for pain
17 management;

18 (9) beneficiary advocacy organizations; and

19 (10) other organizations with expertise in the
20 assessment, diagnosis, treatment, and management
21 of pain, as determined appropriate by the Secretary.

22 (c) CONTENTS.—The report described in subsection
23 (a) shall include the following:

1 (1) An analysis of payment and coverage under
2 title XVIII of the Social Security Act with respect
3 to the following:

4 (A) Evidence-based treatments and tech-
5 nologies for chronic or acute pain, including
6 such treatments that are covered, not covered,
7 or have limited coverage under such title.

8 (B) Evidence-based treatments and tech-
9 nologies that monitor substance use withdrawal
10 and prevent overdoses of opioids.

11 (C) Evidence-based treatments and tech-
12 nologies that treat substance use disorders.

13 (D) Items and services furnished by practi-
14 tioners through a multi-disciplinary treatment
15 model for pain management, including the pa-
16 tient-centered medical home.

17 (E) Medical devices, non-opioid based
18 drugs, and other therapies (including inter-
19 ventional and integrative pain therapies) ap-
20 proved or cleared by the Food and Drug Ad-
21 ministration for the treatment of pain.

22 (F) Items and services furnished to bene-
23 ficiaries with psychiatric disorders, substance
24 use disorders, or who are at risk of suicide, or
25 have comorbidities and require consultation or

1 management of pain with one or more special-
2 ists in pain management, mental health, or ad-
3 diction treatment.

4 (2) An evaluation of the following:

5 (A) Barriers inhibiting individuals entitled
6 to benefits under part A or enrolled under part
7 B of such title from accessing treatments and
8 technologies described in subparagraphs (A)
9 through (F) of paragraph (1).

10 (B) Costs and benefits associated with po-
11 tential expansion of coverage under such title to
12 include items and services not covered under
13 such title that may be used for the treatment
14 of pain, such as acupuncture, therapeutic mas-
15 sages, and items and services furnished by inte-
16 grated pain management programs.

17 (C) Pain management guidance published
18 by the Federal Government that may be rel-
19 evant to coverage determinations or other cov-
20 erage requirements under title XVIII of the So-
21 cial Security Act.

22 (3) An assessment of all guidance published by
23 the Department of Health and Human Services on
24 or after January 1, 2016, relating to the prescribing
25 of opioids. Such assessment shall consider incor-

1 porating into such guidance relevant elements of the
2 “Va/DoD Clinical Practice Guideline for Opioid
3 Therapy for Chronic Pain” published in February
4 2017 by the Department of Veterans Affairs and
5 Department of Defense, including adoption of ele-
6 ments of the Department of Defense and Veterans
7 Administration pain rating scale.

8 (4) The options described in subsection (d).

9 (5) The impact analysis described in subsection
10 (e).

11 (d) OPTIONS.—The options described in this sub-
12 section are, with respect to individuals entitled to benefits
13 under part A or enrolled under part B of title XVIII of
14 the Social Security Act, legislative and administrative op-
15 tions for accomplishing the following:

16 (1) Improving coverage of and payment for pain
17 management therapies without the use of opioids, in-
18 cluding interventional pain therapies, and options to
19 augment opioid therapy with other clinical and com-
20plementary, integrative health services to minimize
21 the risk of substance use disorder, including in a
22 hospital setting.

23 (2) Improving coverage of and payment for
24 medical devices and non-opioid based pharma-
25cological and non-pharmacological therapies ap-

1 proved or cleared by the Food and Drug Administra-
2 tion for the treatment of pain as an alternative or
3 augment to opioid therapy.

4 (3) Improving and disseminating treatment
5 strategies for beneficiaries with psychiatric dis-
6 orders, substance use disorders, or who are at risk
7 of suicide, and treatment strategies to address
8 health disparities related to opioid use and opioid
9 abuse treatment.

10 (4) Improving and disseminating treatment
11 strategies for beneficiaries with comorbidities who
12 require a consultation or comanagement of pain with
13 one or more specialists in pain management, mental
14 health, or addiction treatment, including in a hos-
15 pital setting.

16 (5) Educating providers on risks of coadminis-
17 tration of opioids and other drugs, particularly
18 benzodiazepines.

19 (6) Ensuring appropriate case management for
20 beneficiaries who transition between inpatient and
21 outpatient hospital settings, or between opioid ther-
22 apy to non-opioid therapy, which may include the
23 use of care transition plans.

24 (7) Expanding outreach activities designed to
25 educate providers of services and suppliers under the

1 Medicare program and individuals entitled to bene-
2 fits under part A or under part B of such title on
3 alternative, non-opioid therapies to manage and
4 treat acute and chronic pain.

5 (8) Creating a beneficiary education tool on al-
6 ternatives to opioids for chronic pain management.

7 (e) **IMPACT ANALYSIS.**—The impact analysis de-
8 scribed in this subsection consists of an analysis of any
9 potential effects implementing the options described in
10 subsection (d) would have—

11 (1) on expenditures under the Medicare pro-
12 gram; and

13 (2) on preventing or reducing opioid addiction
14 for individuals receiving benefits under the Medicare
15 program.

16 **SEC. 7. SUSPENSION OF PAYMENTS BY MEDICARE PRE-**
17 **SCRIPTION DRUG PLANS AND MA-PD PLANS**
18 **PENDING INVESTIGATIONS OF CREDIBLE AL-**
19 **LEGATIONS OF FRAUD BY PHARMACIES.**

20 (a) **IN GENERAL.**—Section 1860D–12(b) of the So-
21 cial Security Act (42 U.S.C. 1395w–112(b)) is amended
22 by adding at the end the following new paragraph:

23 “(7) **SUSPENSION OF PAYMENTS PENDING IN-**
24 **VESTIGATION OF CREDIBLE ALLEGATIONS OF FRAUD**
25 **BY PHARMACIES.**—

1 “(A) IN GENERAL.—The provisions of sec-
2 tion 1862(o) shall apply with respect to a PDP
3 sponsor with a contract under this part, a phar-
4 macy, and payments to such pharmacy under
5 this part in the same manner as such provisions
6 apply with respect to the Secretary, a provider
7 of services or supplier, and payments to such
8 provider of services or supplier under this title.

9 “(B) RULE OF CONSTRUCTION.—Nothing
10 in this paragraph shall be construed as limiting
11 the authority of a PDP sponsor to conduct
12 postpayment review.”.

13 (b) APPLICATION TO MA–PD PLANS.—Section
14 1857(f)(3) of the Social Security Act (42 U.S.C. 1395w–
15 27(f)(3)) is amended by adding at the end the following
16 new subparagraph:

17 “(D) SUSPENSION OF PAYMENTS PENDING
18 INVESTIGATION OF CREDIBLE ALLEGATIONS OF
19 FRAUD BY PHARMACIES.—Section 1860D–
20 12(b)(7).”.

21 (c) CONFORMING AMENDMENT.—Section 1862(o)(3)
22 of the Social Security Act (42 U.S.C. 1395y(o)(3)) is
23 amended by inserting “, section 1860D–12(b)(7) (includ-
24 ing as applied pursuant to section 1857(f)(3)(D)),” after
25 “this subsection”.

1 (d) CLARIFICATION RELATING TO CREDIBLE ALLE-
2 GATION OF FRAUD.—Section 1862(o) of the Social Secu-
3 rity Act (42 U.S.C. 1395y(o)) is amended by adding at
4 the end the following new paragraph:

5 “(4) CREDIBLE ALLEGATION OF FRAUD.—In
6 carrying out this subsection, section 1860D–
7 12(b)(7) (including as applied pursuant to section
8 1857(f)(3)(D)), and section 1903(i)(2)(C), a fraud
9 hotline tip (as defined by the Secretary) without fur-
10 ther evidence shall not be treated as sufficient evi-
11 dence for a credible allegation of fraud.”.

12 (e) EFFECTIVE DATE.—The amendments made by
13 this section shall apply with respect to plan years begin-
14 ning on or after January 1, 2020.